Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Radiotherapy + Targeted Therapy + Immunotherapy vs Targeted Therapy + Immunotherapy in Operable HNSCC
NCT07040956Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, afatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Started Jun 2025; status: completed.
02
Drugs
tislelizumabafatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07040956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040956.